Literature DB >> 33161343

Azaindole therapeutic agents.

Damoder Reddy Motati1, Radhika Amaradhi1, Thota Ganesh2.   

Abstract

Azaindole structural framework is an integral part of several biologically active natural and synthetic organic molecules; and several FDA approved drugs for various diseases. In the last decade, quite a number of literature reports appeared describing the pharmacology, biological activity and therapeutic applications of a variety of azaindole molecules. This prompted the organic and medicinal chemistry community to develop novel synthetic methods for various azaindoles and test them for a bioactivity against a variety of biological targets. Herein, we have summarized the biological activity of therapeutically advanced clinical candidates and several preclinical candidate drugs that contain azaindole structural moiety.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BMS626529; Fevipiprant and HIV treatment; Guitarrins; PLX4720; Pexidartinib

Mesh：

Substances：

Year:  2020        PMID： 33161343      PMCID： PMC7736151          DOI： 10.1016/j.bmc.2020.115830

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN： 0968-0896            Impact factor:   3.641


  56 in total

1.  Synthesis and Structure-Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3- b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity.

Authors:  Sven Verdonck; Szu-Yuan Pu; Fiona J Sorrell; Jon M Elkins; Mathy Froeyen; Ling-Jie Gao; Laura I Prugar; Danielle E Dorosky; Jennifer M Brannan; Rina Barouch-Bentov; Stefan Knapp; John M Dye; Piet Herdewijn; Shirit Einav; Steven De Jonghe
Journal:  J Med Chem       Date:  2019-06-12       Impact factor: 7.446

Review 2.  Variolins and related alkaloids.

Authors:  Scott R Walker; Erin J Carter; Belinda C Huff; Jonathan C Morris
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

3.  7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors.

Authors:  Raffaella Cincinelli; Loana Musso; Lucio Merlini; Giuseppe Giannini; Loredana Vesci; Ferdinando M Milazzo; Nives Carenini; Paola Perego; Sergio Penco; Roberto Artali; Franco Zunino; Claudio Pisano; Sabrina Dallavalle
Journal:  Bioorg Med Chem       Date:  2013-12-22       Impact factor: 3.641

4.  Luminescence and reactivity of 7-azaindole derivatives and complexes.

Authors:  Shu-Bin Zhao; Suning Wang
Journal:  Chem Soc Rev       Date:  2010-06-24       Impact factor: 54.564

5.  Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity.

Authors:  Chengbin Yang; Xi Zhang; Yi Wang; Yongtai Yang; Xiaofeng Liu; Mingli Deng; Yu Jia; Yun Ling; Ling-Hua Meng; Yaming Zhou
Journal:  ACS Med Chem Lett       Date:  2017-07-26       Impact factor: 4.345

6.  Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma.

Authors:  Qingqing Zhou; Athena F Phoa; Ramzi H Abbassi; Monira Hoque; Tristan A Reekie; Josep S Font; Renae M Ryan; Brett W Stringer; Bryan W Day; Terrance G Johns; Lenka Munoz; Michael Kassiou
Journal:  J Med Chem       Date:  2017-02-28       Impact factor: 7.446

7.  Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-585248).

Authors:  Alicia Regueiro-Ren; Qiufen M Xue; Jacob J Swidorski; Yi-Fei Gong; Marina Mathew; Dawn D Parker; Zheng Yang; Betsy Eggers; Celia D'Arienzo; Yongnian Sun; Jacek Malinowski; Qi Gao; Dedong Wu; David R Langley; Richard J Colonno; Caly Chien; Dennis M Grasela; Ming Zheng; Pin-Fang Lin; Nicholas A Meanwell; John F Kadow
Journal:  J Med Chem       Date:  2013-02-07       Impact factor: 7.446

8.  Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.

Authors:  Kevin M Foote; J Willem M Nissink; Thomas McGuire; Paul Turner; Sylvie Guichard; James W T Yates; Alan Lau; Kevin Blades; Dan Heathcote; Rajesh Odedra; Gary Wilkinson; Zena Wilson; Christine M Wood; Philip J Jewsbury
Journal:  J Med Chem       Date:  2018-11-10       Impact factor: 7.446

9.  Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.

Authors:  Antonella Ermoli; Alberto Bargiotti; Maria Gabriella Brasca; Antonella Ciavolella; Nicoletta Colombo; Gabriele Fachin; Antonella Isacchi; Maria Menichincheri; Antonio Molinari; Alessia Montagnoli; Antonio Pillan; Sonia Rainoldi; Federico Riccardi Sirtori; Francesco Sola; Sandrine Thieffine; Marcellino Tibolla; Barbara Valsasina; Daniele Volpi; Corrado Santocanale; Ermes Vanotti
Journal:  J Med Chem       Date:  2009-07-23       Impact factor: 7.446

10.  Design, synthesis, and evaluation of 3,5-disubstituted 7-azaindoles as Trk inhibitors with anticancer and antiangiogenic activities.

Authors:  Seunghee Hong; Jinhee Kim; Ju Hyeon Seo; Kyung Hee Jung; Soon-Sun Hong; Sungwoo Hong
Journal:  J Med Chem       Date:  2012-05-18       Impact factor: 7.446
View more
  1 in total

1.  Novel Substituted Purine Isosteres: Synthesis, Structure-Activity Relationships and Cytotoxic Activity Evaluation.

Authors:  Spyridon Dimitrakis; Efthymios-Spyridon Gavriil; Athanasios Pousias; Nikolaos Lougiakis; Panagiotis Marakos; Nicole Pouli; Katerina Gioti; Roxane Tenta
Journal:  Molecules       Date:  2021-12-31       Impact factor: 4.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.